You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Product menu

Alt text Alt text

All PLHIV pictured and quoted in this website have been prescribed every-2-month VOCABRIA + REKAMBYS. They have given consent for the use of their images and words, and have received remuneration from ViiV Healthcare.

Indication: VOCABRIA injection is indicated, in combination with REKAMBYS injection, for the treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the NNRTI and INI class.1,2

INTRODUCING SOLAR

The first head-to-head switch study comparing every-2-month VOCABRIA + REKAMBYS with daily oral therapy3

SOLAR investigated the efficacy, safety and treatment experience of participants who were switched to every-2-month VOCABRIA + REKAMBYS (n=454) vs those who continued daily oral therapy with BIC/FTC/TAF (n=227).3

The SOLAR primary endpoint was met: Every-2-month VOCABRIA + REKAMBYS was virologically non-inferior to daily oral therapy with BIC/FTC/TAF at Month 12 (modified intention-to-treat exposed [mITT-E]: 1.1% [n=5/447] with plasma HIV-1 RNA ≥50 copies/mL vs 0.4% [n=1/223], respectively, adjusted difference = 0.7% [95% CI -0.7%, 2.0%]).3

THE ONLY COMPLETE LONG-ACTING REGIMEN FOR HIV-1 TREATMENT

NA

Addressing challenges

Removes the need for daily oral HIV therapy1,2

 

read more

NA

Proven efficacy

Non-inferior vs daily oral therapy with BIC/FTC/TAF at 12 months3

Sustained efficacy over 3 years1,2

read more

NA

Patient preference

Preferred by 9 out of 10 trial patients over daily oral therapy with BIC/FTC/TAF3

 

read more

*Two months between doses is on the continuation phase of treatment.

BIC/FTC/TAF=bictegravir/emtricitabine/tenofovir alafenamide; CI=confidence interval; HIV=human immunodeficiency virus; HIV-1=human immunodeficiency virus type 1; INI=integrase inhibitor; mITT-E=modified intention-to-treat exposed; NNRTI=non-nucleoside reverse transcriptase inhibitor; PLHIV=people living with HIV; RNA=ribonucleic acid.

Changing the experience of HIV Therapy

Contact us

Request a contact from a GSK x ViiV Representative
References
  1. VOCABRIA Summary of Product Characteristics. ViiV Healthcare; 2023. Available at: https://www.medicines.ie/medicines/vocabria-600-mg-prolonged-release-suspension-for-injection-35220/spc#tabs [Last Accessed: January 2024]
  2. REKAMBYS Summary of Product Characteristics. Janssen-Cilag International NV; 2023. Available at: https://www.medicines.ie/medicines/rekambys-35258/spc [Last Accessed: January 2024]
  3. Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety and tolerability of switching to long-acting cabotegravir + rilpivirine versus continuing bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed adults with HIV, 12 month results (SOLAR): A randomised open-label, phase 3b non-inferiority trial. The Lancet HIV. 2023. Published Online 8th August 2023. https://doi.org/10.1016/S2352-3018(23)00136-4

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

REKAMBYS (rilpivirine long acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under licence by the ViiV Healthcare group of companies.

All other trademarks are owned by the ViiV Healthcare group, or its licensor. 
©2024 GSK group of companies. All rights reserved.

PM-IE-CBR-WCNT-230010
Date of preparation: May 2024